ProShare Advisors
PRME icon

ProShare Advisors’s Prime Medicine PRME Stock Holding History

ProShare Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.9K Sell
22,968
-3,190
-12% -$12.1K ﹤0.01% 1735
2025
Q4 		$90.8K Buy
26,158
+7,059
+37% +$31.4K ﹤0.01% 1888
2025
Q3 		$106K Buy
19,099
+2,228
+13% +$9.05K ﹤0.01% 1836
2025
Q2 		$41.7K Sell
16,871
-1,323
-7% -$2.04K ﹤0.01% 2015
2025
Q1 		$36.2K Sell
18,194
-3,992
-18% -$10.2K ﹤0.01% 1991
2024
Q4 		$64.8K Buy
22,186
+4,375
+25% +$15.4K ﹤0.01% 2148
2024
Q3 		$68.9K Buy
17,811
+5,104
+40% +$23.6K ﹤0.01% 1940
2024
Q2 		$65.3K Sell
12,707
-2,569
-17% -$15.6K ﹤0.01% 1716
2024
Q1 		$107K Buy
15,276
+2,520
+20% +$19.1K ﹤0.01% 1813
2023
Q4 		$113K Buy
+12,756
New +$98.3K ﹤0.01% 1763

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

ProShare Advisors's PRME Position: Q1 2026 in Review

ProShare Advisors reduced its Prime Medicine (PRME) stake by 12% in Q1 2026, selling an estimated $12.1K and leaving 22,968 shares worth $79.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1735.

ProShare Advisors first reported a position in PRME in Q4 2023 and has held it in 10 quarters since. The position peaked at $113K in Q4 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • ProShare Advisors held 22,968 shares of Prime Medicine worth $79.9K as of Q1 2026.
  • ProShare Advisors sold 3,190 Prime Medicine shares in Q1 2026, an estimated $12.1K.
  • Prime Medicine made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1735 holding.
  • ProShare Advisors first reported a position in Prime Medicine in Q4 2023 and has held it in 10 quarters since.
  • ProShare Advisors's Prime Medicine position peaked at $113K in Q4 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.